PEA for Bipolar Depression

A Randomized Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

The purpose of this six-week study is to test a novel antidepressant medication called PEA (palmitoylethanolamide) in addition to a mood stabilizer for patients with Bipolar Disorder. This medication is considered a nutraceutical that works by targeting the endocannabinoid system to reduce inflammation and may help reduce symptoms of depression. The study includes 4 visits with compensation at each visit, totaling $200 over the course of 6 weeks. Eligible participants will receive a clinical evaluation, daily medication with refills free of charge, and regular follow ups with the study doctor. Some visits can be completed virtually for your convenience.

---

Phone: (713) 486-MOOD / (713) 486-6663
Email: [email protected]

---

We are currently Recruiting: Adults age 18-60 with Bipolar Disorder in a current depressive episode and taking a mood stabilizer

Visits: 4 visits

Compensation: $200 over 6 weeks. free daily medication refills, and regular follow-ups.